Survival of genetic subtypes of relapsed myeloma may be modulated by secondary events [5]

Blood

Volumn 109, Issue 8, 2007, Pages 3610-3611

  Chng, Wee J ^b   Mulligan, George ^b   Bryant, Barbara ^b   Bergsagel, Leif ^a  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLIN D;

CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CHROMOSOME 11; CHROMOSOME 15; CHROMOSOME 19; CHROMOSOME 21; CHROMOSOME 3; CHROMOSOME 5; CHROMOSOME 7; CHROMOSOME 9; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; GENE EXPRESSION; HUMAN; LETTER; MULTIPLE MYELOMA; MYELOMA; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; TRISOMY;

EID: 34147191105     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-09-048769     Document Type: Letter

References (4)

1. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64:1546-1558.
2. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005;106:296-303.
3. Mulligan G, Mitsiades C, Bryant B, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2007;109:3177-3188.
4. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006;108:2020-2028.